The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 03, 2025 for Ravi Agrawal, trustee ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Promoter Ravi Agrawal, trustee of Ravi Agrawal Trust (holding 1,62,42,904 shares or 13.00% of Ajanta Pharma), has disclosed creation of pledge on 11,52,777 equity shares and release of pledge on 46,499 shares. The reason for creation is 'Re-Financing' and for release is 'Excess Pledge'. Lenders involved include Emerging India Credit Opportunities Fund, Aditya Birla Capital, Infina Finance, Deutsche Bank, HSBC Direct, and Bajaj Finance. Post-event, the total encumbered shares stand at 71,13,920 (5.69% of share capital), up from around 59,64,476 (4.77%) earlier. Multiple pledge creation and release events were executed on September 29 and September 30, 2025 across various lenders, suggesting a re-financing exercise to consolidate debt obligations.
Net pledged shares rose modestly to 5.69% of capital from ~4.77%, reflecting routine re-financing rather than distress. This is a normal treasury management activity and not a material negative signal for shareholders; existing investors should note the marginally higher encumbrance but the absolute level remains low.